Get the Stockscreener App
1.52
3.75%
-0.08
After Hours:
1.52
Neumora Therapeutics Inc stock is traded at $1.52, with a volume of 1.35M.
It is down -3.75% in the last 24 hours and down -4.35% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$1.60
Open:
$1.55
24h Volume:
1.35M
Relative Volume:
0.71
Market Cap:
$285.60M
Revenue:
-
Net Income/Loss:
$-222.39M
P/E Ratio:
-1.1456
EPS:
-1.3268
Net Cash Flow:
$-193.40M
1W Performance:
-4.94%
1M Performance:
-4.35%
6M Performance:
-56.50%
1Y Performance:
-5.52%
1-Day Range:
$1.46
$1.585
1-Week Range:
$1.46
$1.785
52-Week Range:
$0.8302
$3.65
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.52 | 300.63M | 0 | -222.39M | -193.40M | -1.3268 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-12-26 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-27-25 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-16-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-02-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-10-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-07-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-25 | Downgrade | Stifel | Buy → Hold |
| Jan-02-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
1,849,445 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by Johnson & Johnson - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Wall Street Zen - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Neumora Therapeutics Appoints Joshua Pinto as CEO and Releases Q2 2026 Financial Results - Kalkine Media
Neumora Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
8-K: Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updatemoomoo - moomoo.com
Neumora Therapeutics Cuts Q2 Net Loss to $41.3M on Lower R&D Spend - Minichart
Neumora Appoints New CEO as Q2 Net Loss Narrows to $43.1M - Minichart
Neumora Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Neumora Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Neumora Therapeutics Q2 Results: Net loss narrows to $43.1 million - scanx.trade
Neumora Therapeutics 2Q 2026: Net loss $(43.1M), EPS $(0.23) — 10-Q Summary - TradingView
Neumora Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
NMRA: Pipeline advanced, net loss narrowed, and cash runway extends into Q3 2027 - TradingView
Neumora Therapeutics Reports Second Quarter 2026 Results and Advances Pipeline Amid Leadership Changes - Quiver Quantitative
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - marketscreener.com
Neumora Names Joshua Pinto CEO as 2026 Clinical Milestones Near - Stock Titan
Neumora Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
NMRA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutic - The National Law Review
Neumora Therapeutics (NMRA) Gains 2.48% as Biotech Stock Holds Above $1.57 SupportCatalyst Driven Stocks - dars.gov.et
Perceptive Advisors LLC Takes $9.95 Million Position in Neumora Therapeutics, Inc. $NMRA - MarketBeat
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Holdings Inc. (FTRE) - The Globe and Mail
Neumora Therapeutics, Inc. Revenue Breakdown – NASDAQ:NMRA - TradingView
Neumora Therapeutics Inc. (NMRA) Q1 2026 Earnings: Narrower-Than-Expected Loss on Cost Discipline, Shares SlipMargin Compression Risk - dars.gov.et
Neumora Therapeutics (NMRA) Expected to Release Earnings on Wednesday - MarketBeat
H.C. Wainwright reiterates Neumora stock rating on positive toxicology data By Investing.com - Investing.com Nigeria
Neumora reports favorable toxicology results for obesity drug By Investing.com - Investing.com Nigeria
Neumora Therapeutics | 8-K: Current report - Moomoo
Neumora Therapeutics Shares Rise on Positive Obesity Drug Results - Moomoo
NMRA|Neumora Therapeutics Inc|Price:1.456|Chg%:-0.034 - TradingKey
New toxicology data support advancement of Neumora Therapeutics’ NMRA-215 - BioWorld News
Neumora Therapeutics Plans Q4 IND Filing for Obesity Drug After Repeat Toxicology Study - marketscreener.com
Neumora reports favorable toxicology results for obesity drug - Investing.com
Neumora Therapeutics Reports Favorable Repeat Toxicology Results for NMRA-215 and Plans IND Submission in Q4 2026 - Quiver Quantitative
Neumora's Repeat NMRA-215 Rat Study Found No Unexpected Adverse Findings - Stock Titan
Neumora Therapeutics Inc (NMRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neumora Therapeutics Inc (NMRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NMRA|Neumora Therapeutics Inc|Price:1.490|Chg%:-0.070 - TradingKey
Neumora Therapeutics Inc (NMRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neumora Therapeutics Inc (NMRA) Cash Flow - TradingKey
TradingKey - TradingKey
Neumora Therapeutics (NASDAQ:NMRA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Siren L.L.C. Buys 2,209,039 Shares of Neumora Therapeutics, Inc. $NMRA - MarketBeat
Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7. 2025NMRA - TMX Newsfile
Neumora Therapeutics (NMRA) AGM 2026 Summary - Quartr
Neumora Therapeutics Target of Unusually Large Options Trading (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics (NMRA) Slides to $1.6 as Biotech Sector Headwinds PersistReversal Setup Alerts - dars.gov.et
Neumora Therapeutics (NASDAQ:NMRA) Price Target Cut to $5.00 by Analysts at Royal Bank Of Canada - MarketBeat
Neumora Therapeutics Is Maintained at Outperform by RBC Capital - Moomoo
RBC Cuts Price Target on Neumora Therapeutics to $5 From $7, Keeps Outperform, Speculative Risk - marketscreener.com
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neumora Therapeutics Inc Stock (NMRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pinto Joshua | President |
Feb 17 '26 |
Sale |
3.54 |
5,967 |
21,093 |
57,783 |
| BERNS PAUL L | See Remarks |
Feb 17 '26 |
Sale |
3.51 |
9,819 |
34,459 |
7,395,185 |
| Milligan Michael Lee | See Remarks |
Feb 17 '26 |
Sale |
3.56 |
1,436 |
5,119 |
21,034 |
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):